NCT00110591View on ClinicalTrials.gov

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 16, 2004

Primary Completion Date

November 7, 2005

Study Completion Date

March 31, 2008

Conditions
HIV Infections
Interventions
DRUG

PRO 140

Monoclonal antibody to CCR5

Trial Locations (1)

68502

MDS Pharma Services, Lincoln

Sponsors

Lead Sponsor

CytoDyn, Inc.
All Listed Sponsors
lead

CytoDyn, Inc.

INDUSTRY

NCT00110591 - Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers | Biotech Hunter | Biotech Hunter